Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$36.2 million.

  • Gossamer Bio's Free Cash Flow fell 1290.54% to -$36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.5 million, marking a year-over-year decrease of 1113401.84%. This contributed to the annual value of -$3.5 million for FY2024, which is 9782.1% up from last year.
  • Gossamer Bio's Free Cash Flow amounted to -$36.2 million in Q3 2025, which was down 1290.54% from -$47.1 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Free Cash Flow high stood at $116.3 million for Q2 2024, and its period low was -$53.6 million during Q1 2022.
  • In the last 4 years, Gossamer Bio's Free Cash Flow had a median value of -$38.3 million in 2023 and averaged -$31.5 million.
  • As far as peak fluctuations go, Gossamer Bio's Free Cash Flow skyrocketed by 40416.98% in 2024, and later tumbled by 14049.4% in 2025.
  • Over the past 4 years, Gossamer Bio's Free Cash Flow (Quarter) stood at -$47.8 million in 2022, then soared by 30.12% to -$33.4 million in 2023, then fell by 6.15% to -$35.5 million in 2024, then decreased by 1.93% to -$36.2 million in 2025.
  • Its Free Cash Flow was -$36.2 million in Q3 2025, compared to -$47.1 million in Q2 2025 and -$39.8 million in Q1 2025.